Vitrolife announces changes to the executive management team after the acquisition of Igenomix
As announced on 30 November, 2021, Vitrolife AB (publ) completed the acquisition of Igenomix, as a result, changes will be made to the executive management team effective 1 January, 2022. The executive management team will from 1 January, 2022, consist of:Thomas Axelsson, President and Chief Executive OfficerGroup Functions:Francisco Jiménez, SVP Strategy & Corporate DevelopmentKarin Koritz Russberg, SVP HR & SustainabilityCarlos Simón, Chief Scientific OfficerPatrik Tolf, Chief Financial OfficerBusiness Areas:Claus Bisgaard, SVP Vitrolife TechnologyRicardo Capella, SVP